Abstract: An aircraft propulsion system capable of reducing a rotational load of an engine shaft is provided. An aircraft propulsion system includes a plurality of engines (60-1 and 60-2) and a controller (100). When a flight state is a first state, the controller (100) causes some of the plurality of engines (60-1 and 60-2) to operate while stopping the remaining engine. At least one engine (60-1) of the plurality of engines (60-1 and 60-2) includes a bleed air hole (71-1), a bleed air pipe (72-1), and a bleed air valve (73-1). When causing the engine (60-2) which has stopped to start up again, the controller (100) opens a bleed air valve (73-1) in the engine (60-1) which is in operation and supplies compressed air of the compressor (62-1) to the compression chamber (64-2) of the engine (60-2) which has stopped.

Abstract: Provided is a gas turbine system in which electricity consumption of a battery when starting or stopping a gas turbine engine is reduced and sufficient battery power during flight can be secured. The present invention includes a plurality of gas turbine engines 21, 22, and 23, generators 41, 42, and 43, a battery 5, and a controller 7. The controller 7 decides at least one main starting gas turbine engine 21 from the plurality of gas turbine engines before the plurality of gas turbine engines are started, starts the main starting gas turbine engine 21 using electricity from the battery 5, and starts the secondary starting gas turbine engines 22 and 23 of the plurality of gas turbine engines other than the main starting gas turbine engine 21 using electricity from the generator 41 connected to the main starting gas turbine engine 21 after the main starting gas turbine engine 21 reaches a steady state.

Abstract: Technology for operating an engine smoothly is provided. In an aircraft propulsion system, a controller causes at least a first engine among the plurality of engines to be stopped and causes a second engine, which has not been stopped, to be operated when an aircraft is flying in a prescribed flight mode and causes the first engine to be operated and causes the second engine to be stopped when a detector detects that the temperature related to the first engine is less than or equal to a first prescribed temperature.

Abstract: A folded coil label and associated methods of making a folded coil label are provided. On example folded core label may include a core, a coil, and a capacitor. The coil may be wrapped around the core and connected to the capacitor to form a resonant circuit. The coil may be formed of angled traces wrapped around the core to form turns of the coil, and each angled trace may be electrically and physically connected in series to an adjacent angled trace to form a helical structure of the coil.

Abstract: Manufacturing antennas for a dual tag by: providing a web structure having a dielectric layer between a first metal layer and a second metal layer; depositing a first resist on the first metal layer to define a radio frequency (RF) coil and a first electrode of an RF capacitor; depositing the first resist on the second metal layer to define a second electrode of the RF capacitor; depositing a second resist on the second metal layer to define connection pads for a near field antenna, wherein one of the first resist and the second resist on the second metal layer defines a far field antenna and the near field antenna; and etching the first and second metal layers to form the RF coil, the electrodes of the RF capacitor, the far field antenna, the near field antenna, and the connection pads.

Abstract: A processing apparatus includes a holder configured to hold a substrate; a grinding device configured to perform a grinding on a processing surface of the substrate held on the holder; a transfer device configured to transfer the substrate to the holder; and a controller configured to control the holder, the grinding device and the transfer device. The controller controls the holder, the grinding device and the transfer device to perform performing initialization of the holder, initialization of the grinding device and initialization of the transfer device after the processing apparatus is stopped during an operation thereof and the processing apparatus is restarted; detecting the substrate on the holder; deciding whether the grinding on the detected substrate by the grinding device is required; and performing, by the grinding device, the grinding on the processing surface of the substrate on which the grinding is decided to be required.

Abstract: In one embodiment, a method of manufacturing an RFID label includes providing a web structure comprising a dielectric layer and a metal layer; depositing a non-removable resist on the metal layer, the deposition of the non-removable resist defining an antenna; depositing a removable resist on the metal layer, the deposition of the removable resist defining connection pads for connecting an integrated circuit (IC) to the antenna; etching the metal layer to form the antenna and the connection pads; removing the removable resist from the metal layer to expose the connection pads; and attaching the IC to the connection pads.

Abstract: An object of the present invention is to provide a tumor therapeutic agent and a kit which have superior antitumor effects as compared with gemcitabine, a taxane antitumor agent, and a combination therapy thereof which have been put on the market. According to the present invention, there is provided a tumor therapeutic agent obtained by combining a taxane antitumor agent with a liposome composition in which gemcitabine or a salt thereof is contained in a liposome.

Abstract: An object of the present invention is to provide a tumor therapeutic agent and a kit which have superior antitumor effects as compared with gemcitabine, a taxane antitumor agent, and a combination therapy thereof which have been put on the market. According to the present invention, there is provided a tumor therapeutic agent obtained by combining a taxane antitumor agent with a liposome composition in which gemcitabine or a salt thereof is contained in a liposome.

Abstract: An image reading device includes a magnetizer that magnetizes a metal object attached to a document, a magnetism detector that is disposed on the downstream side of the magnetizer in a document transport direction from a document stacking table toward the document transport path and detects residual magnetism of the metal object, and a metal object accompaniment determination unit that determines whether or not the metal object is attached to the document based on a detection result by the magnetism detector.

Abstract: An object of the present invention is to provide a tumor therapeutic agent and a kit which have superior antitumor effects as compared with gemcitabine, a taxane antitumor agent, and a combination therapy thereof which have been put on the market. According to the present invention, there is provided a tumor therapeutic agent obtained by combining a taxane antitumor agent with a liposome composition in which gemcitabine or a salt thereof is contained in a liposome.

Abstract: An image reading device includes: a document delivery unit for delivering a document loaded on a document loading platform to a document transport path; a flip-up detector for detecting flip-up of the document when the document is delivered; a metal detector for detecting metal attached to the document when the document is delivered; and a staple determination unit for determining whether or not a stapling process is applied to the document based on detection results of the flip-up detector and the metal detector.

Abstract: An optical amplifier includes a polarization splitter, a polarization rotator, first and second optical couplers, and first and second semiconductor optical amplifying devices. The TE polarized wave of light split by the polarization splitter is input to a first input port of the first optical coupler. The TM polarized wave of the split light is converted into a TE polarized wave by the polarization rotator to be input to a second input port of the first optical coupler. First light and second light output from a first output port and a second output port of the first optical coupler are amplified by the first semiconductor optical amplifying device and the second semiconductor optical amplifying device to be input to a first input port and a second input port of the second optical coupler, respectively. Third light is output from an output port of the second optical coupler.

Abstract: An object of the present invention is to provide a combined pharmaceutical formulation obtained by combining a liposome composition and an immune checkpoint inhibitor, in which gemcitabine is encapsulated in a dissolved state in liposomes in the liposome composition. According to the present invention, there is provided a pharmaceutical formulation including (A) a liposome composition in combination with (B) an immune checkpoint inhibitor, in which the liposome composition includes liposomes each having an inner water phase, and an aqueous solution constituting an outer water phase and having the liposomes dispersed therein, gemcitabine is encapsulated in a dissolved state in the liposomes, and the liposome composition and the immune checkpoint inhibitor are administered simultaneously or sequentially.

Abstract: Provided are a liposome composition which has a practically required long-term preservation stability, and which has a release rate of a drug on the order of several tens of hours due to releasability of a drug being able to be suitably controlled by rendering an inner water phase hyper-osmotic; and a method for producing the same. According to the present invention, it is possible to provide a liposome composition, including liposomes each of which has an inner water phase and an aqueous solution which constitutes an outer water phase and in which the liposomes are dispersed, in which the content of cholesterols is 10 mol % to 35 mol % with respect to the total amount of lipid components in the liposome composition, and each of the liposomes encapsulates a drug in a dissolved state, and an osmotic pressure of the inner water phase is 2-fold to 8-fold relative to the osmotic pressure of the outer water phase.

Abstract: Provided are a liposome composition which has a practically required long-term preservation stability, and which has a release rate of a drug on the order of several tens of hours due to releasability of a drug being able to be suitably controlled by rendering an inner water phase hyper-osmotic; and a method for producing the same. According to the present invention, it is possible to provide a liposome composition, including liposomes each of which has an inner water phase and an aqueous solution which constitutes an outer water phase and in which the liposomes are dispersed, in which the content of cholesterols is 10 mol % to 35 mol % with respect to the total amount of lipid components in the liposome composition, and each of the liposomes encapsulates a drug in a dissolved state, and an osmotic pressure of the inner water phase is 2-fold to 8-fold relative to the osmotic pressure of the outer water phase.

Abstract: Provided are a liposome composition in which an osmotic pressure of an inner water phase is 2-fold to 8-fold relative to the osmotic pressure of an outer water phase, and which encapsulates a water-soluble drug in a dissolved state, and also exhibits excellent preservation stability; and a method for producing the same. According to the present invention, it is possible to provide a liposome composition, including liposomes obtained from lipids dissolved and emulsified in an organic solvent, each of which has an inner water phase and an aqueous solution which constitutes an outer water phase and in which the liposomes are dispersed, in which each of the liposomes encapsulates a water-soluble drug in a dissolved state, and an osmotic pressure of the inner water phase is 2-fold to 8-fold relative to the osmotic pressure of the outer water phase; and a method for producing the same.

Abstract: A folded coil label and associated methods of making a folded coil label are provided. On example folded core label may include a core, a coil, and a capacitor. The coil may be wrapped around the core and connected to the capacitor to form a resonant circuit. The coil may be formed of angled traces wrapped around the core to form turns of the coil, and each angled trace may be electrically and physically connected in series to an adjacent angled trace to form a helical structure of the coil.

Abstract: An object of the present invention is to provide a tumor therapeutic agent and a kit which have superior antitumor effects as compared with gemcitabine, a taxane antitumor agent, and a combination therapy thereof which have been put on the market. According to the present invention, there is provided a tumor therapeutic agent obtained by combining a taxane antitumor agent with a liposome composition in which gemcitabine or a salt thereof is contained in a liposome.

Abstract: Provided are a liposome composition which has a practically required long-term preservation stability, and which has a release rate of a drug on the order of several tens of hours due to releasability of a drug being able to be suitably controlled by rendering an inner water phase hyper-osmotic; and a method for producing the same. According to the present invention, it is possible to provide a liposome composition, including liposomes each of which has an inner water phase and an aqueous solution which constitutes an outer water phase and in which the liposomes are dispersed, in which each of the liposomes encapsulates a drug in a dissolved state, an osmotic pressure of the inner water phase is 2-fold to 8-fold relative to the osmotic pressure of the outer water phase, and a release rate of the drug from each of the liposomes is 10%/24 hr to 70%/24 hr in blood plasma at 37° C.; and a method for producing the same.